Mainz Biomed N.V. (MYNZ)
After hours:
| Previous close | 0.8568 |
| Open | 0.8500 |
| Bid | 0.7974 x 100 |
| Ask | 0.8430 x 100 |
| Day's range | 0.8000 - 0.8794 |
| 52-week range | 0.8000 - 6.0000 |
| Volume | |
| Avg. volume | 97,874 |
| Market cap | 17.905M |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Benzinga
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: JNJ) are facing the so-called patent cliffs which imply revenue of tens of billions of dollars between now and and the end of this decade is at risk. The expiration of patents for one or more leading branded products for a company means opening the door to competitors to sell copycats of those drugs, often at a competitive price. But, as always, pharmaceutical companies do their best
- Zacks
What Makes Mainz Biomed NV (MYNZ) a New Buy Stock
Mainz Biomed NV (MYNZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Benzinga
Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening
When it comes to cancer, one cannot overestimate the importance of early detection. Especially when it comes to colorectal and endometrial cancer that even big pharma companies don’t have a good track record at treating. At the end of last year, Merck (NYSE: MRK) provided a non-optimistic update regarding its Phase 3 LEAP-001 trial that evaluates a combined treatment that uses its blockbuster cancer drug, Keytruda, against advanced endometrial carcinoma. The failure of Merck to improve the treat
